相关实验视频

Updated: Jun 30, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

脏置换和拉布多米解的保守疗法:一个回顾性分析

Jonathan de Fallois¹, Robert Scharm², Tom H Lindner¹

¹Medical Department III, Division of Nephrology, University of Leipzig Medical Center, Leipzig, Germany.

|March 15, 2024

概括

脏替代疗法 (KRT) 用于急性脏损伤 (AKI) 来自狂犬病溶解并不能改善肌球蛋白的去除,但与较高的死亡率有关. 持续有毒血过 (CVVH) 显示过器的寿命更短.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
关键护理医学关键护理医学
毒理学毒理学毒理学

背景情况:

轮骨髓溶解可能导致急性损伤 (AKI),并需要置换疗法 (KRT).
快速的肌球蛋白清除对于功能恢复至关重要.
临床证据对KRT在重症监护室的拉布多米解症患者的疗效很少.

研究的目的:

为了比较保守治疗与不同KRT方式在拉布多结溶诱导的AKI.
评估KRT对肌球蛋白消除和临床结果的影响.
确定影响这些患者医院死亡率的因素.

主要方法:

追溯分析了328名患有狂犬病 (肌球蛋白>1000μg/l) 的重症监护患者.
在KRT和保守治疗组之间比较肌球蛋白降低率.
多变量后勤回归以确定死亡率预测因子和KRT模式有效性.
对于体外电路过器寿命的卡普兰-梅尔分析.

主要成果:

171名患者需要KRT;他们在入院时处于更危急的状态.
在KRT (49%) 和保守治疗 (61%) 组 (p=0.082) 中,肌球蛋白减少率相似.
与保守治疗 (18.5%) (p<0.001) 相比,KRT组的住院死亡率明显高 (55.6%).
根据KRT要求 (OR: 2.163) 和SOFA得分 (OR: 1.111) 独立预测死亡率.
没有KRT模式显示出生存益处;CVVH的过器寿命较短 (p=0.017).

结论:

需要KRT治疗的AKI与高死亡率有关.
在KRT方式之间没有观察到肌球蛋白减少的显著差异.
与其他KRT相比,持续毒血过 (CVVH) 显示过器寿命缩短.

关键词:

急性损伤是什么?急性损伤是什么替代疗法是指的替代疗法.线红蛋白的消除线红蛋白的消除拉布多溶解的方法

更多相关视频

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

相关概念视频

Dialysis

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...